Cargando…

Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation

Single sub-anesthetic doses of ketamine can exacerbate the symptoms of patients diagnosed with schizophrenia, yet similar ketamine treatments rapidly reduce depressive symptoms in major depression. Acute doses of the atypical antipsychotic drug clozapine have also been shown to counteract ketamine-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rame, Marion, Caudal, Dorian, Schenker, Esther, Svenningsson, Per, Spedding, Michael, Jay, Thérèse M., Godsil, Bill P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417651/
https://www.ncbi.nlm.nih.gov/pubmed/28472198
http://dx.doi.org/10.1371/journal.pone.0177036
_version_ 1783233928215134208
author Rame, Marion
Caudal, Dorian
Schenker, Esther
Svenningsson, Per
Spedding, Michael
Jay, Thérèse M.
Godsil, Bill P.
author_facet Rame, Marion
Caudal, Dorian
Schenker, Esther
Svenningsson, Per
Spedding, Michael
Jay, Thérèse M.
Godsil, Bill P.
author_sort Rame, Marion
collection PubMed
description Single sub-anesthetic doses of ketamine can exacerbate the symptoms of patients diagnosed with schizophrenia, yet similar ketamine treatments rapidly reduce depressive symptoms in major depression. Acute doses of the atypical antipsychotic drug clozapine have also been shown to counteract ketamine-induced psychotic effects. In the interest of understanding whether these drug effects could be modeled with alterations in neuroplasticity, we examined the impact of acutely-administered ketamine and clozapine on in vivo long-term potentiation (LTP) in the rat’s hippocampus-to-prefrontal cortex (H-PFC) pathway. We found that a low dose of ketamine depressed H-PFC LTP, whereas animals that were co-administrated the two drugs displayed LTP that was similar to a saline-treated control. To address which signaling molecules might mediate such effects, we also examined phosphorylation and total protein levels of GSK3β, GluA1, TrkB, ERK, and mTOR in prefrontal and hippocampal sub-regions. Among the statistically significant effects that were detected (a) both ketamine and clozapine increased the phosphorylation of Ser9-GSK3β throughout the prefrontal cortex and of Ser2481-mTOR in the dorsal hippocampus (DH), (b) clozapine increased the phosphorylation of Ser831-GluA1 throughout the prefrontal cortex and of Ser845-GluA1 in the ventral hippocampus, (c) ketamine treatment increased the phosphorylation of Thr202/Tyr204-ERK in the medial PFC (mPFC), and (d) clozapine treatment was associated with decreases in the phosphorylation of Tyr705-TrkB in the DH and of Try816-TrkB in the mPFC. Further analyses involving phosphorylation effect sizes also suggested Ser831-GluA1 in the PFC displayed the highest degree of clozapine-responsivity relative to ketamine. These results provide evidence for how ketamine and clozapine treatments affect neuroplasticity and signaling pathways in the stress-sensitive H-PFC network. They also demonstrate the potential relevance of H-PFC pathway neuroplasticity for modeling ketamine-clozapine interactions in regards to psychosis.
format Online
Article
Text
id pubmed-5417651
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-54176512017-05-14 Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation Rame, Marion Caudal, Dorian Schenker, Esther Svenningsson, Per Spedding, Michael Jay, Thérèse M. Godsil, Bill P. PLoS One Research Article Single sub-anesthetic doses of ketamine can exacerbate the symptoms of patients diagnosed with schizophrenia, yet similar ketamine treatments rapidly reduce depressive symptoms in major depression. Acute doses of the atypical antipsychotic drug clozapine have also been shown to counteract ketamine-induced psychotic effects. In the interest of understanding whether these drug effects could be modeled with alterations in neuroplasticity, we examined the impact of acutely-administered ketamine and clozapine on in vivo long-term potentiation (LTP) in the rat’s hippocampus-to-prefrontal cortex (H-PFC) pathway. We found that a low dose of ketamine depressed H-PFC LTP, whereas animals that were co-administrated the two drugs displayed LTP that was similar to a saline-treated control. To address which signaling molecules might mediate such effects, we also examined phosphorylation and total protein levels of GSK3β, GluA1, TrkB, ERK, and mTOR in prefrontal and hippocampal sub-regions. Among the statistically significant effects that were detected (a) both ketamine and clozapine increased the phosphorylation of Ser9-GSK3β throughout the prefrontal cortex and of Ser2481-mTOR in the dorsal hippocampus (DH), (b) clozapine increased the phosphorylation of Ser831-GluA1 throughout the prefrontal cortex and of Ser845-GluA1 in the ventral hippocampus, (c) ketamine treatment increased the phosphorylation of Thr202/Tyr204-ERK in the medial PFC (mPFC), and (d) clozapine treatment was associated with decreases in the phosphorylation of Tyr705-TrkB in the DH and of Try816-TrkB in the mPFC. Further analyses involving phosphorylation effect sizes also suggested Ser831-GluA1 in the PFC displayed the highest degree of clozapine-responsivity relative to ketamine. These results provide evidence for how ketamine and clozapine treatments affect neuroplasticity and signaling pathways in the stress-sensitive H-PFC network. They also demonstrate the potential relevance of H-PFC pathway neuroplasticity for modeling ketamine-clozapine interactions in regards to psychosis. Public Library of Science 2017-05-04 /pmc/articles/PMC5417651/ /pubmed/28472198 http://dx.doi.org/10.1371/journal.pone.0177036 Text en © 2017 Rame et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rame, Marion
Caudal, Dorian
Schenker, Esther
Svenningsson, Per
Spedding, Michael
Jay, Thérèse M.
Godsil, Bill P.
Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation
title Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation
title_full Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation
title_fullStr Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation
title_full_unstemmed Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation
title_short Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation
title_sort clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417651/
https://www.ncbi.nlm.nih.gov/pubmed/28472198
http://dx.doi.org/10.1371/journal.pone.0177036
work_keys_str_mv AT ramemarion clozapinecounteractsaketamineinduceddepressionofhippocampalprefrontalneuroplasticityandalterssignalingpathwayphosphorylation
AT caudaldorian clozapinecounteractsaketamineinduceddepressionofhippocampalprefrontalneuroplasticityandalterssignalingpathwayphosphorylation
AT schenkeresther clozapinecounteractsaketamineinduceddepressionofhippocampalprefrontalneuroplasticityandalterssignalingpathwayphosphorylation
AT svenningssonper clozapinecounteractsaketamineinduceddepressionofhippocampalprefrontalneuroplasticityandalterssignalingpathwayphosphorylation
AT speddingmichael clozapinecounteractsaketamineinduceddepressionofhippocampalprefrontalneuroplasticityandalterssignalingpathwayphosphorylation
AT jaytheresem clozapinecounteractsaketamineinduceddepressionofhippocampalprefrontalneuroplasticityandalterssignalingpathwayphosphorylation
AT godsilbillp clozapinecounteractsaketamineinduceddepressionofhippocampalprefrontalneuroplasticityandalterssignalingpathwayphosphorylation